Intra-arterial clot therapy does not lead to higher rate of independent living, researchers determine

Share this article:

Clot-busting devices administered through the artery do not improve victims' chances of living independently after a stroke, according to research published Thursday.

Researchers funded by the National Institute of Neurological Disorders and Stroke (NINDS) undertook a controlled trial with 656 participants. Between 2006-2012, some of the participants received standard drug therapy of intravenous tissue plasminogen activator (tPA). Others received tPA as well as intra-arterial treatment, in which a catheter run through an artery administers tPA directly to large clots in the brain.

Both groups had a similar statistical likelihood of living independently within 90 days of stroke, the researchers found. Of those who received IV tPA alone, 39% were functionally independent within three months. Among the other group, that number was 41%.

The rate of victim disability was similar, even though intra-arterial treatment is 40% more effective than IV tPA at clot removal, the researchers found. However, intra-arterial therapy is also risky, with 16% of study participants experiencing complications.


Share this article:

More in News

CMS expands therapy payment research

The government is expanding its research into alternative therapy payments, to consider more holistic changes to the way Medicare reimburses skilled nursing facilities, the Centers for Medicare & Medicaid Services announced Tuesday.

CDC tightens Ebola guidelines for healthcare workers

The Centers for Disease Control and Prevention has issued more stringent guidelines for how healthcare workers should interact with Ebola patients, following an outcry from nurses and other professionals.

Nonprofit providers face alarming market forces, must rally, LeadingAge chairman says

Nonprofit providers face alarming market forces, must rally, ...

Nonprofit long-term care providers must work together to address alarming trends, or their market share could plummet and the sector as a whole could falter, LeadingAge Chairman David Gehm told ...